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resumo 
 
 
Atualmente, um dos cancros mais incidentes e mortíferos, no homem, 
é o cancro da próstata. O tratamento utilizado para este tipo de cancro é 
eficaz e com elevadas taxas de sucesso quando este é detetado 
precocemente. Contudo, quando a sua deteção ocorre num estadio mais 
avançado, as opções de tratamento existentes apresentam efeitos 
secundários que devem ser tidos em conta na decisão terapêutica. A 
terapia fotodinâmica (PDT) é uma metodologia emergente no tratamento 
de diversas doenças oncológicas, entre outras aplicações, que se baseia 
na utilização combinada de uma molécula fotossensibilizável, luz e 
oxigénio que, quando atuam em conjunto, são capazes de gerar espécies 
reativas de oxigénio citotóxicas no tecido alvo.  
Reconhecendo esta potencialidade, este estudo pretendeu avaliar o 
potencial fotodinâmico de quatro novos fotossensibilizadores de tipo 
porfirínico (PS4a, PS4b, PS5a e PS5b). Os derivados testados 
apresentam na sua estrutura, para além do macrociclo porfirínico, uma 
unidade uracilo fundido com unidades glicosidicas ligada ao macrociclo na 
posição beta-pirrólica. Os derivados PSXa e PSXb apresentam, 
respetivamente, unidades de xilose e galactose quer protegidas (PS4) 
quer desprotegidas (PS5). A atividade citotóxica destes novos derivados 
foi testada em células isoladas de um carcinoma da próstata (PC3) e 
numa linhagem celular prostática não tumoral (PNT-2). Este estudo, in 
vitro, foi feito tanto na presença como na ausência de luz. 
Os resultados obtidos indicam diferentes perfis de citotoxicidade para 
os compostos analisados para ambas as linhas celulares. Assim, de todos 
os compostos testados, o PS4b foi aquele que apresentou fototoxicidade 
nas células tumorais da próstata não afetando as células não tumorais nas 
concentrações estudadas. Os restantes derivados ou apresentam 
citotoxicidade e fototoxicidade para ambas as linhas celulares testadas 
(PS4a e PS5a) ou são particularmente tóxicos para as células não 
tumorais (PS5b). Assim sendo, podemos concluir pela avaliação da 
citotoxicidade e fototoxicidade do derivado PS4b que este apresenta 
propriedades biológicas promissoras revelando-se um potencial candidato 
a ser utilizado como agente fotossensibilizador para tratamento por PDT  
do cancro da próstata, se utilizado nas condições adequadas. 
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abstract 
 
Currently, one of the most incident and deadly cancers, in men, is 
prostate cancer. The treatment used to this type of cancer is efficient and 
with high success rates when early detected. However, when the detection 
occurs in a more advanced stage, the existing treatment options have side 
effects that must be considered in the therapeutic decision. Photodynamic 
therapy (PDT) is an emerging approach in the treatment of various 
oncological diseases, and other applications, based on the combined use 
of a photosensitizer  molecule, light and oxygen which, when acting 
together, are able to generate cytotoxic reactive oxygen species (ROS) in 
the target tissue.   
Recognizing this potential, this study aimed to evaluate the 
photodynamic potential of four new porphyrinic type photosensitizers 
(PS4a, PS4b, PS5a and PS5b). The tested derivatives are porphyrins 
bearing in its beta-pyrrolic positions fused uracils containing a sugar 
moiety. The derivatives PSXa (xylose) and PSXb (galactose) contain their 
sugar units protected (PS4) or unprotected (PS5). The cytotoxic activity of 
these new derivatives was tested in isolated cells from prostate carcinoma 
(PC3) and from a non-tumour prostate cell line (PNT-2). This study, in 
vitro, has been done both in the presence and absence of light. 
 The results point out different cytotoxicity profiles for the tested 
compounds for both cell lines. Thus, the PS4b showed phototoxicity in 
prostate tumour cells without affecting non-tumour cells, at the studied 
concentrations. The remaining derivatives or possessed cytotoxicity and 
phototoxicity for both cell lines tested (PS4a and PS5a) or were particularly 
toxic to non-tumour cells (PS5b). Therefore, we can conclude by the 
cytotoxicity evaluation and phototoxicity that PS4b shows promising 
biological properties revealing to be a potential candidate to be used as a 
photosensitizer for the prostate cancer PDT treatment, if used under the 
right conditions. 
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1.1 General overview on cancer 
Cancer is an emerging public health problem in several parts of the world 
independently if it is a developed or developing country [1], [2]. It is described by 
abnormal cells that can divide without control and can invade tissue and organs of the 
body.  The incidence of this disease is likely to increase due to growth and population 
aging and also lifestyle behaviors such as smoking, poor diet, physical inactivity and 
reproductive changes [2]. 
In European Union, in 2012, were registered over one million (1 417 495) incident 
cancer cases (all sites but non-melanoma skin) and less than one million (707 755) 
cancer deaths [3], [4]. This disease has several psychycological repercussions including 
fear, pain, depression or even anxiety. Along the years, advances in Technology and in 
the diagnostic allow the early detection of the disease. The cancer treatment comprises 
the conventional methods: chemotherapy, surgery and radiotherapy that have some 
severe adverse effects.  
Photodynamic therapy (PDT) has emerged as a promising treatment for numerous 
diseases, including cancer, with less adverse effects than the ones presented by 
conventional treatment [5], [6]. This technique uses a photoactive agent, in cancer cells 
that, followed with light irradiation, allows the trigger of chemical and biochemical 
reactions leading to cell death. 
 
1.2 Prostate cancer 
Prostate cancer (PCa) is still one of the most incident and deathly cancers 
worldwide. According to the GLOBOCAN project (from the International Agency for 
Research on Cancer), PCa is the second most common cancer in men, with nearly 1.1 
million men diagnosed worldwide in 2012, and the fifth leading cause of death from 
cancer in men, accounting for 6.6% of the total men deaths. In Europe, PCa was the 
most common cancer in men, accounting for 343 174 diagnoses, in 2012, and it was 
responsible 71 033 deaths, being classified as the second leading cause of death from 
cancer in men. In Portugal, the scenario is similar (Figure 1) with PCa being the most 
common cancer in men in 2012, as well. With thereabout 23.25% (Age Standardized 
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Rate (European) per 100 000) and was the fourth leading cause of death with 11.06% 
total deaths of PCa [3], [4].  
 
Figure 1- Estimated incidence (left) and estimated mortality (right) of prostate cancer in men in Portugal, in 
2012. Taken from [3], [4]. 
Since the main risk factor for PCa is age, these numbers are expected to increase due 
to population aging [1], [2]. 
 
1.2.1 Risk factors 
Several aspects of PCa development and progression remain to be elucidated. 
However, epidemiological evidences sustain that advanced age, black ethnicity and 
family history of PCa are amongst the most well-established risk factors for the disease 
[7], [8]. While about 30% of men between 30 and 40 years old were detected with small 
prostatic carcinomas, this percentage duplicates when considering men between 60 and 
70 years old [9], [10]. Due to the population aging, PCa incidence is expected to 
increase in the next years. On the other hand, differences in health care systems, 
financial barriers, socio-economic status or even fear of both diagnosis and treatment of 
the disease might explain, at least in part, racial differences. Moreover, since cancer is 
considered a genetic disorder, ethnical genetic and epigenetic alterations might also 
explain why African-American men have increased cell proliferation and metastasis, 
and consequently, more aggressive PCa compared to European-American men [11], 
[12]. Regarding the family history, it is estimated that inheritance is responsible for 
about 10% of PCa cases. Men with first-degree relatives (it can be a brother, father or 
son) with PCa have at least the risk doubled in comparison to general population. In 
contrast, distant relative showed only marginally increased risk [11], [13].  
There are also some findings that indicate that environmental and lifestyle factors 
may affect the risk and progression of PCa, such as body size, eating habits, 
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hypertension, sexual behavior, sexually transmitted diseases (in particular gonorrhea, 
syphilis, Trichomonas vaginalis) and smoking (more associated with PCa mortality 
instead of incidence). With an inverse association with PCa are metabolic syndrome 
(dyslipidemia, body mass index, low HDL cholesterol and high triglycerides), diabetes, 
physical activity, aspirin and nonsteroidal anti-inflammatory drugs. However, 
environmental and lifestyle factors are still debatable [7], [8], [10], [14]–[16]. 
 
1.2.2 Prostate carcinogenesis 
There are four stages and processes underlying PCa initiation and development: 
Proliferative inflammatory atrophy (PIA), Prostatic intraepithelial neoplasia (PIN), 
localized PCa and metastatic prostate cancer. PIA englobes simple atrophy and 
postatriphic hyperplasia associated with variable amounts of inflammatory cells and 
stromal fibrosis. PIN is composed by cells of prostate adenocarcinoma occurring within 
pre-existing prostatic acini/ducts. The high-grade PIN have cells where nuclei are 
enlarged and hyperchromatic and often have prominent nucleoli unlike low-grade PIN 
which most of the cells lacked prominent nucleoli [17]. The cellular and molecular 
events that cause PCa remain unknown but it is well known that age is the most 
significant risk factor for PCa development. Androgens and reactive oxygen species 
(ROS) are also responsible for prostate carcinogenesis because ROS cause oxidative 
damage in epithelial cells that can react with other cellular components initiating a free 
radical chain reaction favoring progression of prostate carcinogenic process. On the 
other hand the prostate gland depend on the androgen signaling for growth and 
androgen suppression may lead to an oxidative status increasing the risk of 
carcinogenesis [18].  Another factor is multiple genetic changes such as activation of 
dominantly acting oncogenes that promote cell proliferation and loss of tumour 
suppressor genes that negatively regulate cell proliferation [19]. Inflammation have a 
potential role in prostatic carcinogenesis and tumour progression. Recent studies have 
suggested that inflammation around prostate cancer is associated with worst case 
scenario and chronic inflammation in benign tissue was predictive of a higher-grade 
disease [20], [21]. Some sexual diseases such as human papilloma virus (HPV) (an 
oncogenic virus) have influence on prostate carcinogenesis and can be independent of 
inflammation [22]. 
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1.2.3 Diagnosis and staging 
Currently, there are three main methods for PCa screening: measurement of blood 
prostate specific antigen (PSA) levels, digital rectal examination (DRE) and transrectal 
ultrasonography (TRUS) [23]. PSA is a glycoprotein produced by normal epithelial 
cells of the prostate gland and was one of the first biomarkers to be established when its 
synthesis was found to be increased in malignant cells and, consequently, its levels 
become elevated in the blood. However, the use of PSA in PCa screening is 
controversial because this molecule is specific for prostate, but not for cancer; so, many 
other diseases (e.g. benign prostate hyperplasia, prostatitis and other urological 
problems) can increase the PSA levels [24], [25]. DRE may detect cancers in the 
peripheral zone, independently of PSA levels, while TRUS – an  invasive technique that 
is helpful in guided biopsies – is poorly specific for PCa, but highly sensitive [26]–[30]. 
The use of these three exams in combination is more reliable than the use of only one of 
them; however, the ultimate diagnosis is only possible by the histopathological analysis 
of prostate biopsies [31]–[38]. 
When the disease is diagnosed, an accurate staging is essential to select the most 
suitable treatment, as well as to infer about the prognosis and to predict tumour behavior 
[39]. In 1992, the TNM system was introduced (T – tumour, N – lymph node, M – 
metastases) to determine the stage of cancers [40] and nowadays the TNM system is 
updated. On the other hand, the standard grading of PCa is performed according to the 
Gleason score that predicts cancer behavior. This pattern is graded on a score from 1 
(least aggressive) to 5 (most aggressive) on the largest available specimen, adding the 
most and second most common patterns with Gleason scores ranging from 2 to 10. The 
Gleason system has significant deficiencies that can have an impact on patient care. For 
example: a Gleason score 7 can represent mostly well-differentiated cancer with a lesser 
component of more poorly differentiated cancer (Gleason 3+4) or mostly poorly 
differentiated cancer with a smaller component of well-differentiated cancer (Gleason 
4+3) and this two are prognostically very different [41], [42]. 
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1.2.4 Treatment 
When detected at early stages, PCa can be eradicated with high rates of success by 
surgical removal. Besides radical prostatectomy, other treatment strategies are available 
and include hormonal therapy, radiotherapy, brachytherapy, cryosurgery and high-
intensity focused ultrasound (HIFU). All these options, however, present important side 
effects that should be taken into account during treatment decision-making. The most 
well-established treatment for various stages of PCa is hormonal therapy which reduces 
serum testosterone levels, however in some cases PCa progress and evolve to an 
androgen-independent state where this therapy is worthless [18]. Radical surgery and 
radiotherapy are the most efficient treatments to localized PCa they are commonly 
associated with urinary, sexual and bowel dysfunctions. Radiotherapy has a high risk of 
biochemical relapse and radiation could lead to the development of radioresistant 
tumours with local and systemic progression. Radiation can also have side effects, such 
as severe damage of epithelial surfaces, infertility and swelling of soft tissues. 
Brachytherapy is, in general, prescribed to patients with lower risk PCa and the side 
effect is associated with urinary domain (incontinence) [43]–[45]. Cryosurgery ablation 
of the prostate and HIFU had emerged as alternative therapies for patients in whom 
radical surgery is not suitable [46], but the use of sophisticated and expensive 
equipment’s makes the procedure too expensive to be routinely applied in the majority 
of the countries. Moreover, the use of these two techniques have some disadvantages, 
such as the requirement of preoperative hormonotherapy or biopsy proven recurrence 
and modification of prostate morphology, turning the follow-up more complex [47]. 
HIFU can also cause retrograde ejaculation [48].  
 
1.3 Photodynamic Therapy 
Photodynamic therapy (PDT) is a minimally invasive method that involves the 
administration of a photoactivated drug [photosensitizer (PS)], its selective 
accumulation in the target tissue, followed by light exposure of the injured area, thereby 
resulting in structural and functional damage of the target tissue [49]. Hence, PDT is 
based on photosensitization – the process that occurs when a PS absorbs light. PS is the 
designation given to molecules that need light (usually 400-800 nm) to be activated to 
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originate a biochemical process [50]. Despite the photophysical and photochemical 
properties of PDT are not completely understood, the following subsection summarize 
what is known about the subject. PDT has several advantages over other traditional 
therapies that are summarized in Table 1 [45]. 
 
Table 1- Photodynamic therapy advantages over traditional treatments [45]. 
 Applied to places where surgery cannot be performed; 
 Patients vulnerable to surgery, chemotherapy or radiation can be treated with 
this modality; 
 Current treatments can cause side effects (nausea and vomiting and in some 
cases depress the immune system); 
 Photosensitizers alone do not exhibit any organ cytoxicity; 
 The presence of photosensitizers in liver and kidney do not damage these 
organs; 
 Used as primary or adjunctive treatment for solid cancers of the bladder, 
esophagus, head and neck, brain, lung, prostate, intraperitoneal cavity, breast 
and skin. 
 
1.3.1 Photophysical and photochemical properties 
When the PS molecule in its ground state (S0) is irradiated with light of appropriate 
wavelength absorb it, change its energetic level to a higher energy state ─ the excited 
singlet state (
1
PS*), and becomes unstable. As a consequence, it tends to release the 
excess of energy in three ways: heat release, emission of light (fluorescence emission) 
or by conversion to an intermediate energy state (triplet state  ─ 3PS*). In this new 
energetic condition, the PS can return to the ground state by two pathways, which are 
classified as type I and type II mechanisms (Figure 2), and both can produce reactive 
oxygens spcies (ROS) responsible for the photodynamic action. In type I mechanism, 
the excited PS (
3
PS*) transfer or accept directly an electron from a substrate present in 
the system. In the presence of molecular oxygen (O2), the radical PS
─● 
or PS
+●
 formed 
from the former reaction, can transfer the acquired electron to O2 generating, for 
instance, the superoxide radical (O2
─●
) and the PS molecule returns to S0. Other ROS 
can be formed under this pathway  (H2O2, HO
●
) which are responsible for cellular 
damage and oxidative stress. In type II reaction, the 
3
PS* transfers its energy directly to 
the molecular oxygen in ground state (
3
O2), resulting in the excited singlet oxygen 
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molecule (
1
O2) and the PS in S0 [51], [52]. The 
1
O2 is extremely oxidant species and 
although its very short  half-life (~ 4.2 µs in water), is able to oxidize the cellular targets 
in a radius of 20 nm [53], [54]. 
 
Figure 2- Photosensitization process and Type I and Type II reactions. 
 
PDT application should be preceded by optimization conditions, namely, light, PS 
and their interaction. This can be achieved by selecting the appropriate PS and the most 
adequate light wavelength for its activation. High irradiances (total energy of exposed 
light across the sectional area of irradiated spot) means more light photons delivered 
that can be responsible for the PS excitation and consequently more ROS can be 
generated per time unit. The used of low dose of PS, applying high light irradiances 
allows to achieve similar PDT responses, without undue morbidity. Another critical 
component, in vivo PDT,  is the time that a PS takes to accumulate in tumour cells and 
not be found in the blood stream. Other aspect to be take into account is the possibility 
of PS to have fluorescence emission ability which can help either tumour visualization 
and delimittion or PS quantification in the target tissue; the loss of fluorescence after 
PDT treatment may indicate tumour ablation or the PS photodecomposition [49], [53]. 
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The presence of oxygen during the PDT treatment has a profound effect on its outcome 
because without oxygen no photodynamic action take place [49]. 
 
1.3.1.1 Light 
There are regulatory agencies approving light sources to be commercially available 
as lasers or light emitting diodes (LEDs). The technological evolution has enabled that 
light sources could be reliably introduced into human organism by means of fiber optic 
cables or the LED itself with ultrasound or computed tomography-guided placement. 
The light selection has to take into account that each PS has a specific wavelength 
window and an intensity required for its successful activation. Some PSs can be 
activated at higher wavelengths (red region of the electromagnetic spectrum), allowing 
for deeper penetration into tissues, while others activate at lower wavelengths (blue 
region) for more superficial illumination. An example of that is Foscan® that can be 
activated at multiple wavelengths, from blue to green to red, allowing for more selective 
illumination depth based on the individual tumours depth and location [53]. Other 
clinical parameters to be considered are the optical properties of the target tissue, 
including reflection, scattering, transmission and absorption. In fact, these aspects might 
explain why, for example, melanoma (which is a pigment-rich tissue) is resistant to 
PDT. Both absorption and scattering of light by the tissue, increase as the wavelength 
decrease [45].  
 
1.3.1.2 Photosensitizers 
PSs agents could be either natural or synthetic molecules that after absorbing light 
are able to transfer part of the absorbed energy to molecular oxygen. For instance, 
chlorophyll derivatives (from plants and bacteria) and porphyrins are excellent PSs 
agents [53]. In fact, in the last three decades several PSs were found and prepared to be 
used in different contexts. Considering the different chemical and biological features 
they were classified into three generation classes: first, second and third generations 
(see Appendix 1: Classes of photosensitizers) [45], [49], [55]–[58].  
Currently, several PS are approved to be used in the treatment of a number of 
diseases [59]; however, not all molecules are suitable to be use as PS in PDT for cancer 
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treatment. In fact, there are a number of requirements when choosing the ideal PS for 
this purpose (Table 2) [45], [60], [61]. The PSs can be administered to patients by either 
oral, intravenous injection or intraperitoneal injection [45]. 
 
Table 2- Requirements for the ideal photosensitizer to be used in cancer treatment. 
The ideal photosensitizer to be used in photodynamic therapy for cancer treatment 
should: 
 Exhibit none or minimal dark toxicity 
 Be activated at wavelengths that allow optimal tissue penetration 
 Be selective for tumour cells and accumulate rapidly within these cells 
 Be activated when desired  
 Generate ROS in an amount sufficient to ultimately trigger cell death 
 Be able to eliminate itself  
 Produce minimal adverse effects during and after therapy, including skin 
photosensitivity and pain 
 Be compatible with other forms of treatments to be used in combined 
therapies  
 Easily made commercially available and inexpensive 
 
1.3.2 Tumour destruction 
PDT can drive tumour destruction by three main distinct ways: (1) direct lethal 
effects on tumour cells; (2) destruction of tumour vasculature, which limits the blood 
supply to the region, or (3) enhancement of the immune response [62]–[64]. 
 
1.3.2.1 Direct lethal effects on tumour cells 
Tumour destruction from PDT can occur by the death programmed pathway 
(apoptosis) and/or non-programmed pathway (necrosis). It is generally believed that the 
type of cell death is related to the doses of PDT applied.   
Apoptosis is a well conserved method, characterized by chromatin condensation, 
cleavage of chromosomal DNA into fragments, cell shrinkage and membrane blebbing 
to eliminate damaged cells. Apoptotic death may be initiated by PDT with lower doses 
ceasing the function of cells that undergo on an orderly and programmed dissolution 
were organelles and plasma membrane tend to retain their structure for a long period. In 
this type of cell death, no inflammatory mediators are released. This process has two 
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major pathways: receptor-mediated or extrinsic pathway and mitochondria-mediated or 
intrinsic pathway. The extrinsic pathway is characterized by the stimulation of tumour 
necrosis factor (TNF) receptors that activate caspase-8 and scaffolding proteins. The 
intrinsic pathway starts when mitochondrial function is disrupted and cytochrome C is 
released to cytosol that binds to Apaf-1 inducing oligomerization activating caspase-9. 
Both pathways activate the initiator caspases activating the effector caspases (caspase-3, 
-6 and -7) [53], [62], [63].  
Taking into account that PS is inside tumour cells, when high light intensity on PS 
concentration is employed, the tumour cells are rapidly ablated by necrosis because 
cellular and sub cellular membrane destruction is rapid with cytoplasm swelling, 
devastation of organelles and disruption of the plasma membrane. The ablation of 
tumour cells can be cause by calcium and metabolic byproducts released leading to 
release cytokines and toxic chemicals creating lethal damage in cells nearby and in vivo 
inflammation [53], [62], [63], [65]. 
 
1.3.2.2 Vascular events 
Endothelial cells of the vascular systems can also concentrate the PS. When PS is 
activated by the specific wavelength several events will occur such as disrupting the 
vascular walls, blood will not flow to the tumour and oxygen will become scarce. After 
this events necrosis is expected and platelets will be activated and will aggregate so a 
rapid loss of blood supply in concert with direct tumour and vascular cell lysis will be a 
lethal event to the tumour. If wavelength is not that high (as explain above the light 
penetrates at lower irradiances) the apoptosis pathways may occur leading to tumour 
hypoxia and destruction but without cytokine and immune activation [53]. 
 
1.3.2.3 Immune system 
PDT does not cause severe negative effects on the host immune system although, 
under certain experimental conditions, can cause short-term and reversible immune 
suppression. Immune response is probably a combination of direct PDT effects on the 
tumour and its vasculature in combination with up regulation of the immune system. 
When PDT induces necrosis of tumours and their vasculature an immune cascade is also 
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initiated and inflammatory mediators (such as cytokines, growth factors and proteins) 
are released. PDT can also activate the expression and production of several cytokines, 
such as Interleukin-1β (IL-1β), IL-2, IL-6, IL-10, TNF-α and granulocyte colony 
stimulating factor (G-CSF), which can play an important role in regulating host immune 
response involving lymphoid and non-lymphoid cells. The release of inflammatory 
mediators stimulates white blood cells (neutrophils) that converge on the treatment 
region. Macrophages phagocytize PDT damage cancer cells and some proteins from 
tumours to CD4 helper T-lymphocytes that activate CD8 cytotoxic T lymphocytes. This 
immune reaction may occur at regional and distant lymphatic tissue. Cytotoxic T cells 
can cause necrosis but can also induce apoptotic pathways whenever tumour cells are 
found, even after PDT is complete [49], [53]. 
 
1.4 Photodynamic therapy and prostate cancer 
The prostate is a good target organ for PDT because prostate cancers are often 
locally confined and techniques already exist for the interstitial administration of 
radiation that are easily adapted. So, this treatment can provide a second chance for cure 
in cases of locally recurrent prostate cancer after prior radiation therapy in which 
salvage options are limited [52]. 
Once a PS shows efficiency in vitro studies it can be taken forward to animal studies 
prior to human studies. The commonly used animal model is dog because they have a 
similar prostate structure [66]. Although studies in dogs are in benign prostates because 
there is no implanted PCa model, there are already some studies with spontaneously 
prostate cancer [67]. 
In vivo studies allows to determine the efficiency, safety and reproducibility of PDT 
with different PSs. There are already some studies done in this area such as 5-ALA 
studies in dunnings R3327 rat prostate adenocarcinoma [68], Tookad
® 
(WST-11) [69], 
PhotoPoint (etiopurpurin dichloride, SnET2) [70] and Temoporfin or Foscan (mTHPC) 
[71], all of them tested in dogs. 
Currently, there are already some PSs being studied in humans. Windahl et al, 
reported for the first time in 1990 the use of PDT in 2 patients with localized prostatic 
cancer using HpD and Photofrin [72]. Another PS in phase I-II tested was 5,10,15,20-
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tetrakis(3-hydroxyphenyl)chlorin (also designated under several denominations: 
mTHPC, Temoporfin, Foscan) that was experienced in men with organ confined 
prostate cancer, in 2002 in 13 patients [73] and in 2006 in 6 patients [74]. 
Protoporphyrin IX (PPIX) is a photosensitizer induced by the exogenous administration 
of 5-aminolevulinic (5-ALA) where six patients receives interstitial PDT, one patient 
received PDT during radical retropubic prostatectomy exposing all of the prostate gland, 
three patients received interstitial transurethral PDT where irradiation of the total 
prostate was needed and in two patients a transperineal approach was used [75]. 
Another trial tested 18 patients with histologically confirmed PCa suggesting that 5-
ALA inducing PPIX is enhanced selectively in human PCa [76]. Other well-known PS 
tested is Motexafin lutetium (MLu or LuTex)  that treat 17 patients who experienced 
locally recurrent disease [77]. Padoporfin (WST-09, Tookad) is a palladium 
bacteriopheophorbide PS that needs a carrier in order to be given intravenously and in 
this study PDT was a method of whole-prostate ablation in 28 patients with recurrent 
localized prostate cancer after the failure of external beam radiotherapy [78], [79]. Other 
trial studied a total of 24 patients with histologically proven recurrent prostate 
carcinoma following definitive radiotherapy [80]. All these studies in humans show side 
effects being the most common skin phototoxicity. To avoid this adverse effect, patients 
must protect from direct sunlight for 6 weeks. Other disadvantages reported in trials are 
sepsis, mild stress incontinence/decrease of urinary function, deterioration in erectile 
function, intraoperative hypotension or even tissue sloughing or rectal injury [74]–[80]. 
The results obtain in all this trials are results of a reduced sampling of man but there are 
other parameters that change such as different PSs and light doses delivery. 
 
1.5 Objective of this thesis 
The objective of this work was to validate the photodynamic potential of the four 
new porphyrinic PSs (PS4a, PS4b, PS5a and PS5b) against two human prostate cell 
lines (PNT-2 and PC-3) by verifying the cytotoxicity and phototoxicity of the 
conjugates in darkness and after red light activation. 
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2.1 Cell culture reagents 
Roswell Park Memorial Institute (RPMI) 1640 Medium was purchase from Gibco, 
Invitrogen (Grand Island, New York, USA). Fetal Bovine Serum (FBS), antibiotics 
(Penicillin/Streptomycin mixture) and trypsin-EDTA were acquired from Hyclone 
(Utah, USA). Alamar Blue (AB) and Trypan Blue (TB) were obtained from 
ThermoFisher (Massachusetts, USA). 
 
2.2 Human prostate cells maintenance  
To test the biological potential of the compounds, two human prostate cell lines 
were used: PNT-2 and PC3. PNT-2 cells (kindly given by Dr. Ricardo Pérez-Tomás, 
University of Barcelona, Spain) are prostate pre-neoplastic epithelial cells, immortalized 
with SV40 genome, whereas PC-3 cells (kindly provided by Dr. Rui Medeiros, 
University of Porto, Portugal) are prostatic adenocarcinoma (grade IV) cells isolated 
from bone metastasis of a 62-years-old Causasian man. 
Cell cultures were monitored by PCR to ensure they were free of mycoplasma. The 
cells grown as monolayers in RPMI 1640 Medium, supplemented with 10% FBS and 
1% antibiotics. Cells were maintained in a MCO-170AICUV incubator (Panasonic 
Healthcare CO., LTD – Hamburg, Germany) at 37 ºC in a humidified 5% CO2 
atmosphere. Cells were passed regularly and the medium was changed two to three 
times a week. Trypsin-EDTA was used to detached cells from the plate during the 
subculturing process. 
 
2.3 Photosensitizers 
In this study, four new porphyrinic PSs were used. PSs were synthesized by the 
Organic Chemistry Group (QOPNA) of the Chemistry Department, University of 
Aveiro (Aveiro, Portugal) and kindly provided by Dr. Maria Amparo F. Faustino. In 
general, the compounds, named PS4a, PS4b, PS5a and PS5b, consisted of uracil and 
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sugar units linked to the porphyrin macrocycle at the-pirrolic position. The chemical 
structures of the PSs tested are depicted in Figure 3.  
 
 
Figure 3- Chemical structures of the four new photosensitizers used in the present study and the 
correspondent molecular weight. 
 
All PSs have a porphyrinic macrocycle and an uracil unit associated to a xylose 
(compounds a) or a galactose (compounds b) skeleton. PS4 (PS4a and PS4b) have the 
hydroxyl groups protected with acetyl groups, while PS5 (PS5a and PS5b) are the 
sugar unprotected derivatives. When the hydroxyl groups are unprotected, the PS shows 
higher solubility in water and physiological media, making it more suitable for use in 
PDT.  
The photophysical properties of the compounds were assessed by Cristina Dias 
during her BSc project (Biochemistry Degree, University of Aveiro, Aveiro, Portugal) 
and are summarized in Table 3. Briefly, these PSs exhibit an intense red color in 
solution and have an absorption spectra characteristic of porphyrin macrocycles: an 
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intense band at 419 nm (Soret band) and four weak bands (Q bands) with maxima at ca. 
515, 552, 592 and 648 nm. All compounds exhibit intense red fluorescence emission 
when exicited with visible light. 
The ability of the compounds PS4a, PS4b, PS5a and PS5b to generate 
1
O2 was also 
evaluated through an indirect chemical method in which the yellow 1,3-
diphenylisobenzofuran (DPBF) is oxidized by 
1
O2, generated in situ upon irradiation of 
the solution containing the PS with red light. As a result, 1,2-dibenzoylbenzene — a 
colorless molecule — is produced, allowing a decay of the DPBF maximum absorption 
if 
1
O2 is present. All the compounds under evaluation demonstrated to be able to 
generate 
1
O2. In fact, all compounds after 15 min of irradiation photodecomposed the 
DPBF more than 50% which opens good forecast for these compounds to be considered 
good candidates for PDT. 
 
Table 3- Photophysical properties of the photosensitizers PS4a, PS4b, PS5a and PS5b, in DMF 
  PS4a PS4b PS5a PS5b 
UV-vis 
Soret band 419 420 419 419 
Q bands 
516, 551, 
592, 647 
515, 552, 
592, 649 
514, 553, 
591, 648 
515, 551, 
593, 647 
      
Singlet 
oxygen 
generation  
52.7% 49.4% 57.3% 60.5% 
 
2.4 Light source for photodynamic therapy 
A Back-Light LED-Setup (AG Photobiophysik, Humboldt-Universität zu Berlin, 
Germany), kindly provided by Dr. Beate Roeder from the Institut fur Physics of 
Humboldt University (Berlin, Germany), which delivers white light (400–800 nm), was 
used in PDT assays. The LED-Setup was covered with a red filter (λ= 630 nm ± 20 nm) 
and cells were expose to red light at an irradiance of 1.28 mW/cm
2
 for 20 min (more 
details in the next subtopics). The light irradiance was measured with a Power Meter 
Coherent FieldMaxII-Top (Coherent, Santa Clara, USA) combined with a Coherent 
PowerSens PS19Q (Coherent, Santa Clara, USA) energy sensor.  
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2.5 Optimization of cell-related parameters 
A first preliminary experiment was performed to find the most suitable cell density 
to be used in the following experiments. To do that, cells were counted using Trypan 
Blue (TB) and plated in 96-well culture plates (100 µL per well) at different cell 
densities (500, 1 250, 2 500, 5 000, 10 000, 20 000 and 40 000 cells per well). Cell 
growth was monitored over time (1, 2, 4, 6, 8 and 24 h after platting) using the 
AlamarBlue (AB) reagent according to the manufacturer’s instructions.  
AB is a water-soluble blue dye consisting of resazurin that is reduced to resorufin —
a red and fluorescent compound — by viable cells. Viable cells continuously convert 
resazurin to resorufin, allowing us to determine the cell viability by direct correlation 
with the percentage of AB reduced. The viability alterations can be monitored by 
measuring the absorbance (570 and 600 nm) or the fluorescence (emission at 590 nm 
with excitation at 560 nm) of the growth media. In the present study, the microplate 
reader Tecan Infinite® 200 PRO series (Tecan, Männedorf, Switzerland) was used to 
perform these measurements. 
The optimization experiment was performed once for both cell lines using two 
replicates of each condition. 
 
2.6 Cytotoxicity assay 
The cytotoxicity of each PS was determined by platting 7 500 cells per well 
(counted using TB) in a 96-well culture plate (100 µL per well) for 24 h at 37 ºC in a 
humidified 5% CO2 atmosphere. The compounds were added in different concentrations 
(1.00x10
-4 
M, 1.00x10
-5 
M, 1.00x10
-6 
M, 1.00x10
-7 
M and 1.00x10
-8 
M) to each cell line 
and incubated in light-restricted conditions. Cells without treatment and cells treated in 
1% DMSO (the solvent in which the compounds were prepared) were used as controls. 
Cell viability was analyzed 2, 4, 6, 8 and 24 h after treatment by calculating the 
percentage of AB reduction as described above. This experiment was performed in 
duplicate and using two replicates of each condition per experiment. 
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2.7 Photodynamic therapy Assay 
For the phototoxicity assays, cells (7 500 cells per well, counted using TB) were 
placed in a 96-well culture plate for 24 h at 37 °C in a humidified 5% CO2 atmosphere. 
Compounds were added at different concentrations (1.00x10
-4 
M, 1.00x10
-5 
M and 
1.00x10
-6 
M) and incubated for 4 h. Cells without treatment and cells treated in 1% 
DMSO (the solvent in which the compounds were prepared) were used as controls. 
After that time, the 96-well culture plate was positioned on a Back-Light LED-Setup 
and irradiated with red light (λ= 630 nm ± 20 nm) with an irradiance of 1.28 mW.cm-2 
during 20 min. After irradiation the medium was replaced by fresh complete growth 
medium (without compounds) and the cells were incubated in light-restricted conditions 
for an additional 24 h. Cell viability was assessed using AB assay as described above, 
but additionally to the absorbance measurements (570 and 600 nm) the fluorescence 
was also measured (emission at 590 nm and absorption at 560 nm) using the Tecan 
Infinite® 200 PRO series. A plate with exactly the same experimental conditions and 
handled the same way, but not irradiated was used as negative control for PDT. This 
experiment was performed in triplicate with three replicates of each condition being 
measured in each experiment.  
 
2.8 Statistical analysis 
Data from the optimization experiments and the cytotoxicity assays were analysed 
using Excel (version 2016) and line charts were produced to represent cell viability 
along time. 
For the photodynamic therapy and assessement of cell viability assays, an initially 
exploratory data analysis (EDA) was conducted using graphical techniques (bar charts, 
box and scatter plots) and quantitative analysis (statistical measures and frequency 
tables) in order to characterize each condition, detect possible extreme outliers and 
measurement error. Following this first approach, and in order to identify the statistical 
significant alterations in the percentage of AB reduced, Mann-Whitney tests of the 
equality of means for independent samples (the assumptions of the test were first 
verified) were conducted using IBM SPSS Statistics Software 22. The significance level 
was set at 0.05. 
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3.1 Optimization of the experimental conditions 
As a first approach, preliminar experiments were performed to determine the 
adequate cell density and incubation time for both PNT-2 and PC3 cell lines, to be used 
in the subsequent experiments. To that end, cells were plated at different densities and 
cell growth was monitorized for 24 h using the AB reagent (as described in detail in the 
Material and Methods section) (Figure 4). The percentage of AB reduction was 
calculated as follows below: 
 
               
                         
                             
     
 
where, ελ1 and ελ2 are constants representing the molar extinction coefficient of AB 
at 570 and 600 nm which represent the oxidized (εox) and reduced (εred) forms, 
respectively: Aλ1 and Aλ2 represent absorbance of the test wells at 570 and 600 nm, 
respectively, and A’λ1 and A’λ2 represent the absorbance of negative control (cells 
treated with 1% DMSO) at 570 and 600 nm, respectively. 
When performing experiments using cell cultures, the number of cells initially 
plated and the incubation time should be carefully choosed. Hence, since our goal was 
to study cell viability in response to different treatment conditions it was important to be 
sure that cells were in the logarithmic phase of growth when performing the assay. The 
graphs depicted on Figure 4 show that the growth rate of PNT-2 and PC3 cells is 
different: PC3 have an increased cell growth rate when compared to PNT-2. Knowing 
that PC3 are prostatic adenocarcinoma cells and PNT-2 are prostate pre-neoplasic 
epithelial cells, these results were expected. 
Therefore, based on the results and the factors described above, and since it was 
decided to incubate the cells with the compounds for 24 h, we choosed to start the 
experiments with 7 500 cells per well in the following experiments. Using this cell 
density, we guaranteed that cells were in the logarithmic phase of growth and also that 
we didn’t reach the saturation point of the dye used in the assay (for the PNT-2 cell line 
the percentage of AB reduction was around 40% (Figure 4A) and for the PC3 cell line it 
was around 70% (Figure 4B)). 
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Figure 4- Growth curve of PNT-2 and PC3 cell lines determined using the Alamar Blue (AB) reagent. PNT-2 
(A) and PC3 (B) cells were plated at various densities (500, 1 250, 2 500, 5 000, 10 000, 20 000 and 40 000 cells) in a 
96-well plate and the growth was assessed after 1, 2, 4, 6, 8 and 24 h of incubation. Each experimental condition was 
performed once in duplicate using AB assay. 
 
3.2 Preliminary cytotoxicity assay 
One of the most important features of an ideal PS is the absence or minimal 
cytotoxicity under non-irradiating conditions. Therefore, before starting PDT assays, we 
analyzed eventual intrinsic cytototoxic effects of the four compounds in both cell lines. 
For that, the cell viability of PNT-2 and PC3 cells was determined after incubation with 
each PS (PS4a, PS4b, PS5a and PS5b), at different concentrations (1.00x10
-4 
M, 
1.00x10
-5 
M, 1.00x10
-6 
M and 1.00x10
-7 
M), during 24 h, in light-restricted conditions. 
As controls of these experiments we used cells without any PS addiction and cells 
treated only with 1% DMSO – since the compounds were previously dissolved in 
DMSO. This DMSO control was important to understand if the alterations observed in 
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the cells treated with the PS were due to the DMSO or the compounds themselves. 
Figures 5 and Figure 6 show the effect of each compound on PNT-2 and PC3 cell 
viability after 2, 4, 6, 8 and 24h of PS contact. 
 
Figure 5 - Effect of PS4a (top image) and PS4b (bottom image) on the viability of PNT-2 (graphs A and C, 
respectively) and PC3 (graphs B and D, respectively) cell lines in light-restricted conditions. Cells were 
incubated with PS4a and PS4b at different concentrations (1.00x10-4 M, 1.00x10-5 M, 1.00x10-6 M and 1.00x10-7 M) 
along time (2, 4, 6, 8 and 24 h). Cells and cells treated with 1% DMSO were used as controls. Cell viability was 
assessed using the Alamar Blue (AB) reagent. Data are presented as the mean value referent to one experiment 
performed with two replicates for each condition. 
 
The dark toxicity of PS4a and PS4b for PNT-2 and PC3 vary with the PS as it can 
be seen (Figure 5). We observed that PS4a have a smaller decrease in cell viability in 
both cell lines, namely for the higher concentrations tested, i.e., as higher is the 
concentration lower is the percentage of AB reduction. Instead, the PS4b have opposite 
results. This means that the control (cells incubated in RPMI) have lower percentage of 
AB reduced and PS4b seems to induce cell viability with a direct correlation of 
concentrations tested (this means, as higher is the concentration higher is the percentage 
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of reduction of AB). The PS5a and PS5b were also tested (see Figure 6) and the results 
were similar to PS4a; we observed a decrease in cellular viability in PNT-2 and PC3 
cell lines when were compared the percentage of AB reduction values ones obtain for 
cell control with the control (cells incubated in RPMI) but there was not a correlation 
within and cell viability. 
 
 
Figure 6 - Effect of PS5a (top image) and PS5b (bottom image) on the viability of PNT-2 (graphs A and C, 
respectively) and PC3 (graphs B and D, respectively) cell lines in light-restricted conditions. Cells were 
incubated with PS5a and PS5b at different concentrations (1.00x10-4 M, 1.00x10-5 M, 1.00x10-6 M and 1.00x10-7 M) 
along time (2, 4, 6, 8 and 24 h). Cells and cells treated with 1% DMSO were used as controls. Cell viability was 
assessed using the Alamar Blue (AB) reagent. Data are referent to one experiment performed with two replicates for 
each condition. 
 
Other interesting result is that cells treated with 1% DMSO did not seems to have a 
substantial difference from the control of cells only. After this, we can see, in all PSs for 
both cell lines, that 1% DMSO did not affect cell viability and for that this control “cells 
and DMSO” start’s to be our main control. This happens due to all new PSs were 
diluted in DMSO and in medium culture. DMSO in high percentage can kill cells but at 
1% in all conditions that does not happen and do not influence cell growth and viability. 
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 In short, Figure 5 and Figure 6 present our first approach to have a general idea 
about the intrinsic cytotoxicity of each compound in both cell lines. Although the results 
showed some cytotoxicity in light-restricted conditions, we considered that it does not 
have a meaningful influence on cell viability and prompted us to perform the PDT 
studies. 
However, we excluded the lowest condition since concentrations below 10
-6
 are not 
photocytotoxic under PDT conditions used (data not shown). 
 
3.3 Photodynamic therapy 
In PDT assays, we analyzed the percentage of AB reduction after treatment with 
PS4a, PS4b, PS5a or PS5b, at three different concentrations (1.00x10
-4 
M, 1.00x10
-5 
M 
and 1.00x10
-6 
M). The experiments were done in 96-well plates using three replicates 
for each condition and three independent experiments were performed. To facilitate the 
comprehension of the results, they were divided by cell line.  
As explained in the Materials and Methods section, the stock solution of all 
compounds were diluted in DMSO. Hence, we first verified the impact of the DMSO 
concentration used (1% DMSO) in cell viability, both in presence and absence of the 
light source of our PDT assays (Figure 7). All PDT results were monitorized for 24 h 
using the AB reagent (as described in detail in the Material and Methods section). The 
percentage of AB reduction was calculated as follows below: 
 
               
                                              
                        
     
 
where,  FI = Fluorescent Intensity at 590 nm after sample excitation at 560 nm. The 
test agent was each condition used and the untreated control is cells treated with 1% 
DMSO, except when we analized the 1% DMSO effects on cells were untreated control 
was only cells. 
As shown in Figure 7, the difference between the two conditions (cells and cells 
with 1% DMSO) were not significant and, therefore, were not thought to compromise 
the results (P-value<0.05). In PDT experiments both controls — cells and cells treated 
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with 1% DMSO — were performed, but we used the last one as our main negative 
control. 
 
 
 
Figure 7- Cytotoxic and photocytotoxic effects of 1% DMSO in PNT-2 (graphs A and B, respectively) and PC3 
(graphs C and D, respectively) cell lines. Cells were treated with 1% DMSO or left untreated and incubated in light-
restricted conditions for 24 h. After this incubation period, one of the cell plates was exposed to red light (λ= 630 nm 
± 20 nm) with an irradiance of 1.28 mW.cm-2 during 20 min, while the other remained in light-restricted conditions. 
Both plates were further incubated for (24 h). Cytotoxicity and phototoxicity were then assessed using the Alamar 
Blue reagent. Data are presented as the mean value ± S.D. of three independent experiments, each with three 
replicates of each condition. Non-parametric tests for comparing independent samples were used to assess the 
statistical significance of the results (P-value<0.05). 
 
3.3.1 Effect of the photosensitizers in PNT-2 cell line 
PNT-2 cells were treated with PS4a, PS4b, PS5a or PS5b, at three different 
concentrations (1.00x10
-4 
M, 1.00x10
-5 
M, 1.00x10
-6 
M), for 24 h, in light-restricted 
conditions. The percentage of AB reduction in each condition was calculated to assess 
the intrinsic cytotoxic effect of each compound in PNT-2 cells (Figure 8). 
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Figure 8- Percentage of AB reduced by concentration (1.00x10-4 M, 1.00x10-5 M, 1.00x10-6 M) with treatment 
(PS4a, PS4b, PS5a and PS5b) in PNT-2 cell line, in the absence of light. Cytotoxicity was assessed by AB assay 
24 h after supposed PDT. The percentage of cytotoxicity was calculated relatively to control cells (cells incubated in 
RPMI with 1% DMSO). Data are the mean value ± S.D. of three independent experiments performed in triplicates. 
Non-parametric test for comparing two independent samples. *- difference is significant at the P-value<0.05. 
 
As shown in Figure 8, PS5a and PS5b at the highest concentration tested (1.00x10
-4
 M) 
led to a significant reduction of cell viability when compared to non-treated cells (P= 
0.024 and P= 0.024, respectively). However, no significant differences were found 
between cell viability of cells treated with these compounds comparing to the direct 
control of cells treated with 1% DMSO. Concentrations tested, as well as the other PSs, 
did not shown to have significant impact in cell viability. As this test represents the 
intrinsic cytotoxicity of each PS in PNT-2 cells, because no PDT was applied, we might 
conclude that none of the conditions tested are cytotoxic for these cells in the dark.  
The application of PDT to the same conditions led to different observations (Figure 
9). At the highest concentration (1.00x10
-4 
M) PS5a and PS5b, show to be phototoxic 
when compared to non-treated cells (P= 0.024 and P= 0.024, respectively) and when 
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compared to direct control (P= 0.040 and P= 0.024, respectively). At 1.00x10
-5 
M, PS5b 
was the only PS that show phototoxicity (P= 0.024) when compared to non-treated cells. 
At 1.00x10
-6 
M, PS4a and PS5b presented phototoxicity when compared to non-treated 
cells (P= 0.024 and P= 0.024, respectively). Yet, in this two last conditions (at 1.00x10
-5 
M and 1.00x10
-6 
M), no significant differences were found for these compounds when 
comparing to the direct control of cells treated with 1% DMSO. As well, the rest of the 
concentrations tested and the other PSs, did not  revealed significant impact in PNT-2 
cell viability.  
 
 
Figure 9- Percentage of AB reduced by concentration (1.00x10-4 M, 1.00x10-5 M, 1.00x10-6 M) with treatment 
(PS4a, PS4b, PS5a and PS5b) in PNT-2 cell line, after PDT. Photocytotoxicity was assessed by AB assay 24 h 
after PDT. The percentage of photocytotoxicity was calculated relatively to control cells (cells incubated in RPMI 
with 1% DMSO). Data are the mean value ± S.D. of three independent experiments performed in triplicates. Non-
parametric test for comparing two independent samples. *- difference is significant at the P-value<0.05. 
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3.3.2 Effect of the photosensitizers in PC3 cell line 
The same procedure was made for PC3 cell line, where PC3 cells were treated with 
PS4a, PS4b, PS5a and PS5b, at three different concentrations (1.00x10
-4 
M, 1.00x10
-5 
M, 1.00x10
-6 
M), in the absence of light. The percentage of AB reduction in each 
condition was calculated to assess the intrinsic cytotoxic effect of each compound in 
PNT-2 cells (Figure 10). 
 
 
Figure 10- Percentage of AB reduced by concentration (1.00x10-4 M, 1.00x10-5 M, 1.00x10-6 M) with treatment 
(PS4a, PS4b, PS5a and PS5b) in PC3 cell line, in the absence of light. Cytotoxicity was assessed by AB assay 24 
h after supposed PDT. The percentage of cytotoxicity was calculated relatively to control cells (cells incubated in 
RPMI with 1% DMSO). Data are the mean value ± S.D. of three independent experiments performed in triplicates. 
Non-parametric test for comparing two independent samples. *- difference is significant at the P-value<0.05. 
 
In general, in the tested concentrations (1.00x10
-4 
M, 1.00x10
-5 
M, 1.00x10
-6 
M) the PSs 
did not cause cytotoxicity to PC3 cells. Only it was observed (Figure 10) that PS4b at 
the highest concentration tested (1.00x10
-4 
M) led to a significant reduction of cell 
viability when compared to non-treated cells (P= 0.024) and the same happens to PS5a 
at 1.00x10
-5 
M (P=0.024). For this conditions described above, no significant 
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differences were found between cell viability of cells treated with these compounds and 
cell viability of the direct control of cells treated with 1% DMSO.  The other conditions 
tested did not shown a significant impact in cell viability. As we can observe, this test 
allow us to understand the intrinsic cytotoxicity of each PS in PC3 cells, because it was 
realized in the absence of light, and for that we might conclude that none of the 
conditions tested are cytotoxic for these cells (except PS4b at 1.00x10
-4 
M and PS5a at 
1.00x10
-5 
M).  
With the application of light (PDT) to the same conditions led to different 
observations (Figure 11).  
 
 
Figure 11- Percentage of AB reduced by concentration (1.00x10
-4
 M, 1.00x10
-5
 M, 1.00x10
-6
 M) with treatment 
(PS4a, PS4b, PS5a and PS5b) in PC3 cell line, after PDT. Photocytotoxicity was assessed by AB assay 24 h after 
PDT. The percentage of photocytotoxicity was calculated relatively to control cells (cells incubated in RPMI with 1% 
DMSO). Data are the mean value ± S.D. of three independent experiments performed in triplicates. Non-parametric 
test for comparing two independent samples. *- difference is significant at the P-value<0.05.  
 
At the highest concentration, all the PSs shown phototoxicity when compared to 
non-treated cells (P= 0.024, for all PSs) and PS4a, PS5a and PS5b shown phototoxicity 
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(still at 1.00x10
-4 
M) when compared to direct control that are cells treated with 1% 
DMSO (P= 0.048, P= 0.024 and P= 0.024, respectively). At 1.00x10
-5
 M, PS4b shown 
phototoxicity only when compared to non-treated cells (P= 0.024) and at 1.00x10
-6 
M, 
only PS4a presented phototoxicity when compared to non-treated cells (P= 0.024). 
Nevertheless, at 1.00x10
-5
 M and at 1.00x10
-6
 M the PSs that have significant 
differences for cells non-treated did not have significant differences for these 
compounds when comparing to the direct control of cells treated with 1% DMSO. 
Additionally, the rest of the concentrations tested and the other PSs, did not  revealed 
significant impact in cell viability.  
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Porphyrins are the most commonly used drugs in cancer treatment by PDT and they 
were the first approved PS for PDT of tumours [81]. The association of porphyrins to 
carbohydrates, like galactose or xylose, should improve their efficiency in PDT 
treatment of tumours since it modulates the compound solubility, reaching the tumour 
cells easily, enhanced uptake and improve PS penetration trough cell membranes [82]. 
In this study, we assess the effectiveness of four new PSs molecules to induce 
phototoxicity in two different human prostate cell lines PNT-2 and PC3. 
Usually, one of the first step in this type of studies is to determine the cell uptake of 
the compounds, which allows to find the optimal PS concentration and best incubation 
time of different PSs concentrations to perform the PDT experiments. However, when 
we tried to measure the PS (PS4a, PS4b, PS5a and PS5b) uptake by PNT-2 and PC3 
cell lines at different concentration along time by fluorescence spectroscopy we came 
across with a technical problem because the emission and absorption values were too 
high for the spectrophotometer available. As an alternative we tried to assess the cellular 
uptake by fluorescence microscopy, under the conditions used, but autofluorescent 
signal from the cells increased the background noise, thereby difficulting the analysis of 
the uptake. 
We started with incubations of 24 h at the preliminary study to analyze the intrinsic 
toxicity of each compound. Given the mentioned difficulties, we decided to focus our 
attention in previously published studies to establish our initial experimental conditions, 
such as the incubation time and the PSs concentrations [83]–[87], and that’s why we 
decreased the incubation time for 4 h, when performing the PDT assays. We kept the 
replacement of the growth medium and 24 h incubation after irradiation.  
As explained in the Introduction section, an ideal PS for PDT should exhibit 
minimal or no toxicity when the cells are in light-restricted conditions, being activated 
only upon irradiation at a specific wavelength. To understand how our compounds 
behave regarding their cytotoxic potential before irradiation, PNT-2 and PC3 cells were 
incubated in light-restricted conditions at various concentrations (1.00x10
-4
 M, 1.00x10
-
5
 M, 1.00x10
-6 
M and 1.00x10
-7 
M) and their viability was monitorized (measurements 
were performed 2, 4, 6, 8 and 24 h after the addition of the compounds). With this first 
preliminary experiment, we also wanted to verify if the vehicle itself (DMSO) did not 
influence the reduction of AB. In these preliminary results (Figure 5 and Figure 6) the 
PSs seems does not show dark toxicity. 
4. Discussion 
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In what concerns the use of DMSO as solvent for all compounds it is described on 
literature that DMSO influence cell viability due to its cytotoxic effect. However, our 
results indicate that the concentration we used (1% DMSO) has minimal influence on 
cell growth. The results are in according with the literature, when similar concentrations 
of DMSO (1% DMSO) were used [88]. 
For PDT assay, cells treated with PS4a, PS4b, PS5a and PS5b for 4 h were 
irradiated with red light (λ= 630 nm ± 20 nm) at an irradiance of 1.28 mW/cm2 for 20 
min. Cell viability was then assessed 24 h after irradiation using AB reagent. To test the 
effect of PDT on cell viability using these compounds, control experiments using non-
irradiated cells were performed. The results point out that the tested PSs do not have 
selectivity for cancer cells, under the conditions tested. 
In each experiment, two 96 well-plate were prepared: one for PDT and the other to 
maintain in light-restricted conditions to be used as negative control. As inferred 
initially by the preliminar experiment depicted in Figure 5 and Figure 6, the percentages 
of AB reduction calculated for the control conditions (no treatment and 1% DMSO) 
were not statistically different between them in none of the conditions (Figure 7). The 
results of phototoxic effects of the four PSs are shown in Figure 9 and Figure 11, and it 
will be discussed according to literature [83]–[87]. In PNT-2 cells, the pre-neoplasic cell 
line, the compound PS4a and PS4b did not show neither phototoxicity nor cytotoxicity 
effects. This is an interesting result because it two PSs do not have any effect in PNT-2 
cell line, showing relevance for PDT treatment. The compounds PS5a and PS5b, Figure 
8, showed some cytotoxicity at 1.00x10
-4
 M and, as it was expected, the same happened 
when PDT was applied (Figure 9). In fact, PS5b showed phototoxic effects in all 
concentrations tested. This is relevant because if the PSs are cytotoxic in the absence of 
light, when PDT is applied the same result or more inhibition of cell growth is expected 
to be observed. 
For the PC3 cell line, the neoplasic androgen-independent cell line, the results were 
different from those obtained for PNT-2 (Figure 10 and Figure 11). When comparing 
the outcomes on PC3 cell line without PDT and when PDT is applied, PS4a showed 
some phototoxicity at 1.00x10
-4
 M and 1.00x10
-6 
M, but none cytotoxicity. This means 
that at 1.00x10
-6 
M this compound inhibit cell growth when PDT is applied but do not 
affect the cell viability when PDT is not applied. At 1.00x10
-4
 M and 1.00x10
-6 
M, 
PS4b also showed phototoxicity, but not cytotoxicity. Besides that, this PS4b seems to 
4. Discussion 
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be a trend for cancer cells and as such would be interesting to further study their 
properties and to optimize condition in order to maximize its selectivity. PS5a shows 
phototoxicity and cytotoxicity effects in both cell lines, being more pronounced at 
1.00x10
-4
 M. PS5b presented cytotoxicity for PNT-2 cell line at 1.00x10
-4
 M and no 
cytotoxicity in PC3 cell line. However, it was observed phototoxicity in PNT-2 cell line 
in all concentrations tested and in PC3 cell line is only phototoxic at 1.00x10
-4
 M. 
Briefly, among all new four PSs tested the most promising seems to be PS4b, once 
presented phototoxicity at PC3 cell line. This could happen due to its structure — PS4b 
has galactose in the structure that is described to improve PDT treatment [82]. The fact 
that PS4b has the hydroxyl group protected with acetyl groups (diminish the solubility 
in physiological media) but could increase its interaction with cellular components. It 
was expected the best PS to be PS5b. In this case and maybe due to higher solubility 
this PS present cytotoxicity and phototoxicity in PNT-2 and PC3 cell lines. 
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5. CONCLUSION AND FUTURE 
PERSPECTIVES
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In the present study we intended to assess the cytotoxic and phototoxic action of four 
new porphyrinic PSs in human prostate cell lines — PNT-2 and PC3 cells, which represent 
pre-neopolastic and neoplastic states, respectively. Although structurally different, all of 
these conjugates have a common purpose of being potentially useful to use in PDT, and 
thereby targeting cells to death. The results here obtained show that any compound, under 
the tested conditions, have selectivity for PNT-2 or PC3 cell line either in the absence or in 
the presence of light. In fact, PS5b was phototoxic in all concentrations tested and 
cytotoxic at 1.00x10
-4
 M in PNT-2 cell line and the same does not happen in PC3 cell line, 
that only shows phototoxicity at 1.00x10
-4
 M. This result is not as good as needed for a 
good PS because preferentially the PS should only inhibit the growth of tumoural cells and 
not the healthy cells. Thus, so far we could exclude the PS5b for being a good PS for PDT 
in PCa treatment, under the tested conditions. The same situation occurs for PS5a and 
PS4a that show phototoxicity and cytotoxicity in both cell lines, normally, at the higher 
concentration. For this, are also excluded for being considered a good PS for PDT in PCa 
treatment. For PS4b the results are promising and make this PS molecule a good candidate 
for PDT in PCa treatment. This  potential is due to the fact that this PS4b does not show 
cytotoxicity and phototoxicity at PNT-2 cells and only show phototoxicity in PC3 cell line 
at the higher and medium concentration tested. To conclude, PS4b encourages us to move 
on to the next step: cellular and subcellular localization and to optimize the PDT 
conditions.  
 
For the reasons stated above, there is a great interest to continue the study of these 
compounds. The next steps will be to analyze the uptake of each PS, even if it is by 
fluorescence spectroscopy or by fluorescence microscopy, to aprimorate the conditions 
used for each. The analysis of the their subcellular distribution  by confocal microscopy 
will also be of prime importance to understand their potential mechanism of action. The 
study of the cell signalling pathways altered by the uptake of the compounds, particularly 
the analysis of oxidative stress and cell death-related pathways, is also interesting and 
important to increase our knowledge about the mechanism of action of each PS. Another 
option, and after define uptake, is to test cytotoxicity and phototoxicity of all PSs in 
different human cell lines (preferentially tumoural and non-tumoural). Ultimately, it would 
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be interesting to optimize the most potential PS, in order to increase their effect in cancer 
cells. 
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Table 4 - Classes of photosensitizers 
 Description Disadvantages Examples (Substance) 
First 
generation 
Porphyrinic-based compounds and include 
hematoporphyrin derivatives (HpD); 
Efficacious in the treatment of many cancer 
types; 
 
Complex mixture with uncertain 
structure; 
Lack of tumour selectivity; 
Low absorption of light and poor light 
penetration (short wavelength 
absorption); 
Prolonged skin photosensitivity; 
Photofrin (HpD - first approved PS); 
Photogem (HpD) 
 
Second 
generation 
Have longer wavelength absorption (650-700 
nm); 
The quantity of ROS produced is higher 
compared with first generation PSs; 
Structures include porphyrins, expanded 
porphyrins,chlorins, chlorophyll derivatives; 
bacteriochlorophyll; Phthalocyanines 
 
 Tookad (Bacteriochlorophyll); 
Antrin (Lutexaphyrin); Foscan or 
Temoporfin( 5,10,15,20-tetrakis(3-
hydroxiphenyl)Chlorin); Visudyne or 
Verteporfin (chlorin); Radachlorin 
(chlorophyll-a derivative); Photosens and 
PC4 (Phthalocyanine); Purlytin (tin 
etiopurpurin) 
Prodrugs: Levulan (aminolevulinic acid 
(ALA)); Metvix (methyl aminolevulinate 
(M-ALA)); Hexvix (hexaminolevulinate 
(H-ALA)); 
 
Third 
generation 
1
st
 and 2
nd
 generation PSs associated with 
other components, such as: monosaccharide, 
peptides, monoclonal antibodies, antibody 
fragments, lipoproteins, polymeric 
nanoparticles and liposomes; 
Selective accumulation and better targeting of 
tumour cells; 
Conjugation improves the internalization 
process leading to the enhancement of PDT 
cytotoxicity/efficiency; 
 LS11 and Laserphyrin and Talaporfin 
(aspartylchlorin ); 
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